Kymera Therapeutics (NASDAQ:KYMR) had its target price decreased by stock analysts at Morgan Stanley from $74.00 to $69.00 in a research note issued on Tuesday, Benzinga reports. The brokerage presently has an “equal weight” rating on the stock. Morgan Stanley’s price target suggests a potential upside of 46.75% from the stock’s previous close.
Other equities research analysts also recently issued reports about the company. HC Wainwright assumed coverage on Kymera Therapeutics in a research report on Friday, December 4th. They issued a “buy” rating on the stock. Zacks Investment Research raised Kymera Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, January 13th. Three investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $48.67.
NASDAQ KYMR opened at $47.02 on Tuesday. Kymera Therapeutics has a fifty-two week low of $25.43 and a fifty-two week high of $91.92. The company’s 50-day moving average is $57.51.
Kymera Therapeutics (NASDAQ:KYMR) last posted its earnings results on Thursday, March 11th. The company reported ($0.29) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.14) by ($0.15). The business had revenue of $12.80 million during the quarter, compared to the consensus estimate of $21.60 million. The business’s revenue for the quarter was up 611.1% compared to the same quarter last year. On average, equities research analysts anticipate that Kymera Therapeutics will post -1.38 EPS for the current year.
In other news, insider Jared Gollob sold 8,887 shares of Kymera Therapeutics stock in a transaction that occurred on Friday, February 19th. The shares were sold at an average price of $55.09, for a total value of $489,584.83. Following the completion of the transaction, the insider now owns 99,997 shares in the company, valued at $5,508,834.73. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Bruce Booth sold 229,350 shares of Kymera Therapeutics stock in a transaction that occurred on Friday, March 12th. The shares were sold at an average price of $56.50, for a total transaction of $12,958,275.00. The disclosure for this sale can be found here. Insiders have sold 280,787 shares of company stock worth $15,898,710 over the last ninety days.
Several large investors have recently bought and sold shares of the company. Norges Bank bought a new position in shares of Kymera Therapeutics in the fourth quarter valued at approximately $930,000. JPMorgan Chase & Co. bought a new position in shares of Kymera Therapeutics in the fourth quarter valued at approximately $1,369,000. Jane Street Group LLC bought a new position in shares of Kymera Therapeutics in the fourth quarter valued at approximately $215,000. HighVista Strategies LLC bought a new position in shares of Kymera Therapeutics in the fourth quarter valued at approximately $1,061,000. Finally, Nuveen Asset Management LLC bought a new position in shares of Kymera Therapeutics in the fourth quarter valued at approximately $2,408,000. Institutional investors own 37.83% of the company’s stock.
Kymera Therapeutics Company Profile
Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. It engages in developing IRAK4 program for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; and STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases.
Further Reading: Buyback
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]